Lenvatinib Plus VIC-1911 in Lenvatinib-unresponsive or Lenvatinib-resistant HCC
Status:
Not yet recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This is a prospective clinical study aiming to test the safety and efficacy of lenvatinib in
combination with Aurora kinase A inhibitor VIC-1911 in participate with
lenvatinib-unresponsive or lenvatinib-resistant hepatocellular carcinoma(HCC).